These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 10226769)
1. Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. Becquemont L; Funck-Brentano C; Jaillon P Fundam Clin Pharmacol; 1999; 13(2):232-6. PubMed ID: 10226769 [TBL] [Abstract][Full Text] [Related]
2. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754 [TBL] [Abstract][Full Text] [Related]
3. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Neuvonen PJ; Kantola T; Kivistö KT Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477 [TBL] [Abstract][Full Text] [Related]
4. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Kantola T; Backman JT; Niemi M; Kivistö KT; Neuvonen PJ Eur J Clin Pharmacol; 2000 Jun; 56(3):225-9. PubMed ID: 10952477 [TBL] [Abstract][Full Text] [Related]
5. Effects of CYP3A inhibition on the metabolism of cilostazol. Suri A; Forbes WP; Bramer SL Clin Pharmacokinet; 1999; 37 Suppl 2():61-8. PubMed ID: 10702888 [TBL] [Abstract][Full Text] [Related]
6. The interaction of diltiazem with lovastatin and pravastatin. Azie NE; Brater DC; Becker PA; Jones DR; Hall SD Clin Pharmacol Ther; 1998 Oct; 64(4):369-77. PubMed ID: 9797793 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976 [TBL] [Abstract][Full Text] [Related]
8. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Kyrklund C; Backman JT; Neuvonen M; Neuvonen PJ Br J Clin Pharmacol; 2004 Feb; 57(2):181-7. PubMed ID: 14748817 [TBL] [Abstract][Full Text] [Related]
9. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579 [TBL] [Abstract][Full Text] [Related]
10. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Wandel C; Kim RB; Guengerich FP; Wood AJ Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697 [TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Jacobson TA Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. Aberg JA; Rosenkranz SL; Fichtenbaum CJ; Alston BL; Brobst SW; Segal Y; Gerber JG; AIDS; 2006 Mar; 20(5):725-9. PubMed ID: 16514303 [TBL] [Abstract][Full Text] [Related]
13. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Becquemont L; Neuvonen M; Verstuyft C; Jaillon P; Letierce A; Neuvonen PJ; Funck-Brentano C Clin Pharmacol Ther; 2007 May; 81(5):679-84. PubMed ID: 17301736 [TBL] [Abstract][Full Text] [Related]
14. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Hulskotte EG; Feng HP; Xuan F; Gupta S; van Zutven MG; O'Mara E; Wagner JA; Butterton JR Antimicrob Agents Chemother; 2013 Jun; 57(6):2582-8. PubMed ID: 23529734 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. Kovarik JM; Hartmann S; Hubert M; Berthier S; Schneider W; Rosenkranz B; Rordorf C J Clin Pharmacol; 2002 Feb; 42(2):222-8. PubMed ID: 11831546 [TBL] [Abstract][Full Text] [Related]
17. Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers. Wong SL; Cao G; Mack R; Granneman GR Int J Clin Pharmacol Ther; 1998 Mar; 36(3):146-51. PubMed ID: 9562230 [TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of pravastatin tablet formulations assessed in Korean males. Bae SK; Kim EJ; Lim CH; Lee JS; Kim YG; Lee MG Int J Clin Pharmacol Ther; 2004 May; 42(5):301-6. PubMed ID: 15176654 [TBL] [Abstract][Full Text] [Related]
19. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Lilja JJ; Kivistö KT; Neuvonen PJ Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065 [TBL] [Abstract][Full Text] [Related]
20. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Baner K; Benet LZ; Sewing KF; Christians U J Pharmacol Exp Ther; 1999 Oct; 291(1):131-9. PubMed ID: 10490896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]